Oral antispastic drugs in nonprogressive neurologic diseases

2004125 citationsReview

Authors

Eva Montané · Sociedad Española de Farmacología Clínica

Antonio Vallano · Sociedad Española de Farmacología Clínica

J R Laporte · Sociedad Española de Farmacología Clínica

Abstract

Evidence on the efficacy of oral antispastic drugs in NPND is weak and does not include evaluation of patients' quality of life. If any, efficacy is marginal. Adverse drug reactions were common. Better methodologic instruments are needed for the evaluation of antispastic treatment.

Topics & Keywords

Botulinum Toxin and Related Neurological Disorders Neurological disorders and treatments Neurological and metabolic disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology

Volume 63, Issue 8, pp. 1357-1363

DOI: 10.1212/01.wnl.0000141863.52691.44

Field-Weighted Citation Impact: 2.73